Oncology Drug Reference Sheet: Tafasitamab-Cxix
Chelsea Backler MSN, APRN, AGCNS-BC, AOCNS®, VA-BC
Voice
Description
Tafasitamab-cxix (Monjuvi®) received accelerated approval from the U.S. Food and Drug Administration in July 2020 in combination with lenalidomide for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
ONS Drug Education
Short summaries of newly approved oncology-related therapies or drugs with new indications.
View All Drug Education